Levocetirizine dihydrochloride

Levocetirizine dihydrochloride (CAS 130018-87-0), also referenced under the brand name Xyzal, is the active pharmaceutical ingredient (API) used in second-generation antihistamine formulations.

As the pharmacologically active enantiomer of cetirizine, it is sourced by pharmaceutical manufacturers for finished dosage form production targeting allergic conditions and respiratory relief.

The primary commercial application is in oral solid dosage forms, such as tablets and film-coated tablets, where it functions as the active ingredient in prescription and OTC antihistamine products.

Oral solution and syrup formulations represent a distinct supply channel, particularly for pediatric product lines requiring liquid-compatible API grades for precise dosing and stability.

Topical and dermatological formulations in the personal care and cosmetics space also utilize this ingredient where anti-allergic skin relief claims are pursued under applicable regulatory frameworks.

Levocetirizine dihydrochloride is supplied as a white crystalline powder. It is available in USP, BP, and Ph. Eur. compendial grades, supporting regulatory submissions across major markets.

Packaging is typically offered in controlled quantities suitable for pharmaceutical manufacturing environments, with documentation including CoA, DMF references, and impurity profiles upon request.